135 related articles for article (PubMed ID: 26600401)
1. Compliance of Glaucoma Patients to Ocular Hypotensive Medications Among the Saudi Population.
Osman EA; Alqarni BA; AlHasani SS; Al Harbi SS; Gikandi PW; Mousa A
J Ocul Pharmacol Ther; 2016; 32(1):50-4. PubMed ID: 26600401
[TBL] [Abstract][Full Text] [Related]
2. A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP).
Atkinson MJ; Stewart WC; Fain JM; Stewart JA; Dhawan R; Mozaffari E; Lohs J
Health Qual Life Outcomes; 2003 Nov; 1():67. PubMed ID: 14617372
[TBL] [Abstract][Full Text] [Related]
3. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review.
Olthoff CM; Schouten JS; van de Borne BW; Webers CA
Ophthalmology; 2005 Jun; 112(6):953-61. PubMed ID: 15885795
[TBL] [Abstract][Full Text] [Related]
4. [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France].
Bron A; Nordmann JP; Baudouin C; Rouland JF; Kadi A; Sartral M
J Fr Ophtalmol; 2003 Nov; 26(9):895-903. PubMed ID: 14631273
[TBL] [Abstract][Full Text] [Related]
5. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
[TBL] [Abstract][Full Text] [Related]
6. Level of adherence to ocular hypotensive agents and its determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia.
Mehari T; Giorgis AT; Shibeshi W
BMC Ophthalmol; 2016 Aug; 16():131. PubMed ID: 27485739
[TBL] [Abstract][Full Text] [Related]
7. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.
Lusthaus JA; Goldberg I
Expert Opin Investig Drugs; 2016 Oct; 25(10):1201-8. PubMed ID: 27548834
[TBL] [Abstract][Full Text] [Related]
8. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
9. Protocol-driven adjustment of ocular hypotensive medication in patients at low risk of conversion to glaucoma.
Chan PP; Leung CK; Chiu V; Gangwani R; Sharma A; So S; Congdon N
Br J Ophthalmol; 2015 Sep; 99(9):1245-50. PubMed ID: 25733528
[TBL] [Abstract][Full Text] [Related]
10. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
11. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients.
Day DG; Sharpe ED; Atkinson MJ; Stewart JA; Stewart WC
Eye (Lond); 2006 May; 20(5):583-90. PubMed ID: 15933751
[TBL] [Abstract][Full Text] [Related]
12. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and correlates of self-reported nonadherence with eye drop treatment: the Belgian Compliance Study in Ophthalmology (BCSO).
Vandenbroeck S; De Geest S; Dobbels F; Fieuws S; Stalmans I; Zeyen T
J Glaucoma; 2011 Sep; 20(7):414-21. PubMed ID: 21048510
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
Christiansen GA; Nau CB; McLaren JW; Johnson DH
Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
[TBL] [Abstract][Full Text] [Related]
15. [Reasons for intraocular pressure to resist hypotensive therapy in glaucoma patients].
Onishchenko AL; Kolbasko AV; Safronova MA; Isakov IN
Vestn Oftalmol; 2016; 132(3):49-51. PubMed ID: 27456565
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension.
Ge J; Sun XH; Wang NL; Zhao JL; Wu LL; Chen XM; Wang ZX; Li B
Chin Med J (Engl); 2010 Jun; 123(11):1417-21. PubMed ID: 20819599
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Katz LJ; Simmons ST; Craven ER
Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
[TBL] [Abstract][Full Text] [Related]
18. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.
Trattler W; Noecker RJ; Earl ML
Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298
[TBL] [Abstract][Full Text] [Related]
19. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma.
Rees G; Leong O; Crowston JG; Lamoureux EL
Ophthalmology; 2010 May; 117(5):903-8. PubMed ID: 20153902
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
